{"id":"phase-1-olanzapine","safety":{"commonSideEffects":[{"rate":"~10-15%","effect":"Weight gain"},{"rate":"~20-30%","effect":"Sedation"},{"rate":"~5-10%","effect":"Metabolic syndrome / hyperglycemia"},{"rate":"~5-10%","effect":"Hyperlipidemia"},{"rate":"~5%","effect":"Akathisia"},{"rate":"~5%","effect":"Orthostatic hypotension"},{"rate":"~10-15%","effect":"Prolactin elevation"}]},"_chembl":{"chemblId":"CHEMBL3989694","moleculeType":"Small molecule","molecularWeight":"718.83"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Olanzapine antagonizes dopamine D2 receptors in the mesolimbic and mesocortical pathways, reducing psychotic symptoms, while also blocking serotonin 5-HT2A receptors which may enhance antipsychotic efficacy and reduce extrapyramidal side effects. It also has activity at multiple other receptors including muscarinic, histamine H1, and alpha-adrenergic receptors, contributing to its side effect profile.","oneSentence":"Olanzapine is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:50:36.622Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Bipolar I disorder (acute mania and maintenance treatment)"},{"name":"Treatment-resistant depression (as adjunctive therapy)"}]},"trialDetails":[{"nctId":"NCT05693935","phase":"PHASE3","title":"A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy and Safety of TV-44749 in Adults With Schizophrenia","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D LLC","startDate":"2023-01-24","conditions":"Schizophrenia","enrollment":675},{"nctId":"NCT07455955","phase":"PHASE2","title":"Personalized Antiemetic Regimen According to Patients' Pharmacogenetic Profile","status":"NOT_YET_RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2026-06-03","conditions":"Breast Cancer","enrollment":200},{"nctId":"NCT05303064","phase":"PHASE3","title":"Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder","status":"RECRUITING","sponsor":"Alkermes, Inc.","startDate":"2022-06-30","conditions":"Schizophrenia, Bipolar I Disorder","enrollment":220},{"nctId":"NCT05814640","phase":"PHASE1, PHASE2","title":"Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD)","status":"RECRUITING","sponsor":"First Affiliated Hospital of Chongqing Medical University","startDate":"2023-02-20","conditions":"Depression, Sequestra","enrollment":520},{"nctId":"NCT04216329","phase":"PHASE1","title":"Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-07-07","conditions":"Gliosarcoma, Newly Diagnosed, Glioblastoma","enrollment":11},{"nctId":"NCT06253546","phase":"PHASE1","title":"Safety, Tolerability, and Pharmacokinetic Study of TV-44749 in Chinese Patients With Schizophrenia","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2024-03-28","conditions":"Schizophrenia","enrollment":24},{"nctId":"NCT04503668","phase":"PHASE3","title":"Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients","status":"TERMINATED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2020-12-28","conditions":"Gynecologic Cancer","enrollment":62},{"nctId":"NCT05805800","phase":"PHASE3","title":"Olanzapine and 5-HT3 With or Without Dexamethasone to Prevent CINV","status":"COMPLETED","sponsor":"Xingchen Peng","startDate":"2023-04-15","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":275},{"nctId":"NCT03510325","phase":"PHASE3","title":"Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments(SMART-CAT)","status":"COMPLETED","sponsor":"Shanghai Mental Health Center","startDate":"2019-02-12","conditions":"Schizophrenia","enrollment":762},{"nctId":"NCT03578081","phase":"PHASE3","title":"Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2018-11-20","conditions":"Malignant Neoplasm","enrollment":690},{"nctId":"NCT06107803","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Co-Administration of Roluperidone and Olanzapine in Adult Subjects With Moderate to Severe Negative Symptoms of Schizophrenia","status":"COMPLETED","sponsor":"Minerva Neurosciences","startDate":"2023-10-13","conditions":"Negative Symptoms in Schizophrenia","enrollment":17},{"nctId":"NCT00512070","phase":"NA","title":"Melatonin Metabolism Abnormality in Patients With Schizophrenia or Schizoaffective Disorder Treated With Olanzapine","status":"COMPLETED","sponsor":"Seattle Institute for Biomedical and Clinical Research","startDate":"2007-07","conditions":"Schizophrenia, Schizoaffective Disorder, Bipolar Disorder","enrollment":40},{"nctId":"NCT03030417","phase":"PHASE1","title":"Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-02-27","conditions":"Solid Tumors, Lymphoma","enrollment":36},{"nctId":"NCT03557931","phase":"PHASE2","title":"A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2018-07-13","conditions":"Schizophrenia","enrollment":233},{"nctId":"NCT05242874","phase":"PHASE3","title":"Anti-emetic Prophylaxis With or Without Dexamethasone","status":"COMPLETED","sponsor":"Henan Cancer Hospital","startDate":"2022-02-01","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":442},{"nctId":"NCT00159796","phase":"PHASE3","title":"3-week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07009)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-12-14","conditions":"Bipolar Disorder","enrollment":489},{"nctId":"NCT00159744","phase":"PHASE3","title":"3-Week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07008)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-11-30","conditions":"Bipolar Disorder","enrollment":488},{"nctId":"NCT06554613","phase":"PHASE2","title":"Olanzapine Impact on First-line Immunotherapy for Advanced EGFR-negative NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital of Nanchang University","startDate":"2024-12-01","conditions":"Non-Small Cell Lung Cancer","enrollment":156},{"nctId":"NCT00212784","phase":"PHASE3","title":"Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-09-04","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":1225},{"nctId":"NCT06251635","phase":"NA","title":"Effects of Antipsychotics on Brain Insulin Action in Females","status":"RECRUITING","sponsor":"Centre for Addiction and Mental Health","startDate":"2024-06-03","conditions":"Insulin Resistance, Menstrual Cycle, Type 2 Diabetes","enrollment":15},{"nctId":"NCT05403580","phase":"PHASE3","title":"Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Patients With Advanced Cancer","status":"WITHDRAWN","sponsor":"Mayo Clinic","startDate":"2022-06-03","conditions":"Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm","enrollment":""},{"nctId":"NCT06331520","phase":"PHASE3","title":"NEPA Combined With Olanzapine, Dexamethasone-sparing for the Effect of CINV in Patients Receiving HEC Regimens","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2024-05-01","conditions":"Chemotherapy-induced Nausea and Vomiting, Highly Emetogenic Chemotherapy","enrollment":627},{"nctId":"NCT04987658","phase":"PHASE1","title":"Phase 1 Study of OLZ/SAM in Pediatric Subjects With Bipolar I Disorder","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2021-07-22","conditions":"Bipolar I Disorder","enrollment":7},{"nctId":"NCT05547100","phase":"PHASE1","title":"Study of the Breast Milk Pharmacokinetics of Olanzapine and Samidorphan","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2022-09-14","conditions":"Focus of Study is on Healthy Lactating Women","enrollment":12},{"nctId":"NCT00568672","phase":"PHASE3","title":"Optimal Duration of Olanzapine Add-on Therapy in Major Depression","status":"WITHDRAWN","sponsor":"Charite University, Berlin, Germany","startDate":"2007-10","conditions":"Relapse Rate of a Major Depressive Episode, Safety of Olanzapine in Subjects With Major Depression","enrollment":""},{"nctId":"NCT00845026","phase":"PHASE2","title":"A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients","status":"COMPLETED","sponsor":"Denovo Biopharma LLC","startDate":"2009-03","conditions":"Schizophrenia","enrollment":261},{"nctId":"NCT01052103","phase":"PHASE2","title":"A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms","status":"COMPLETED","sponsor":"Denovo Biopharma LLC","startDate":"2010-01","conditions":"Schizophrenia","enrollment":167},{"nctId":"NCT04437017","phase":"PHASE3","title":"Olanzapine or Dexamethasone, With 5-HT3 RA and NK-1 RA, to Prevent CINV","status":"COMPLETED","sponsor":"Fifth Affiliated Hospital, Sun Yat-Sen University","startDate":"2020-02-03","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":557},{"nctId":"NCT05202275","phase":"PHASE2","title":"The Optimization of Antiemetic Regimen for C-RINV in LA-HNSCCs","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2020-12-01","conditions":"Nausea, Vomiting, Head and Neck Squamous Cell Carcinoma","enrollment":43},{"nctId":"NCT03451734","phase":"","title":"Optimizing and Individualizing the Pharmacological Treatment of First-episode Schizophrenic Patients","status":"COMPLETED","sponsor":"Central South University","startDate":"2018-01-23","conditions":"Schizophrenia, Metabolic Syndrome","enrollment":2000},{"nctId":"NCT04536558","phase":"PHASE3","title":"Olanzapine Plus Fosaprepitant Standard Antiemetic Therapy in the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients Receiving High Emetic Risk Multi-day Chemotherapy: a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2020-10-01","conditions":"Solid Tumor Patients Receiving High Emetic Risk Multi-day Chemotherapy","enrollment":352},{"nctId":"NCT03960151","phase":"PHASE2","title":"Rolapitant Plus Olanzapine in Multiday Cisplatin Chemotherapy","status":"WITHDRAWN","sponsor":"Costantine Albany","startDate":"2018-05","conditions":"Germ Cell Tumor","enrollment":""},{"nctId":"NCT03478605","phase":"PHASE2","title":"Trial to Evaluate Efficacy of Olanzapine With Short-acting 5HT3 Inhibitors in Chemotherapy-induced Nausea & Vomiting (CINV) Prophylaxis","status":"UNKNOWN","sponsor":"Blokhin's Russian Cancer Research Center","startDate":"2018-05-25","conditions":"Emesis, Vomiting, Nausea Post Chemotherapy","enrollment":130},{"nctId":"NCT01248195","phase":"PHASE4","title":"Optimization of Treatment and Management of Schizophrenia in Europe","status":"COMPLETED","sponsor":"Rene Kahn","startDate":"2011-05","conditions":"Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder","enrollment":479},{"nctId":"NCT02484911","phase":"PHASE3","title":"Aprepitant ,Olanzapine,Palonosetron and Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting","status":"COMPLETED","sponsor":"First Affiliated Hospital of Harbin Medical University","startDate":"2015-05","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":120},{"nctId":"NCT02462473","phase":"PHASE2","title":"A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-05","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":9},{"nctId":"NCT02804568","phase":"PHASE1","title":"A Phase 1 Safety Study in Adults With Schizophrenia","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2016-06","conditions":"Schizophrenia","enrollment":42},{"nctId":"NCT02850445","phase":"NA","title":"Trial and Follow-up of the Efficacy of Two-stage Integrated Treatment for Chinese Schizophrenia Inpatients","status":"UNKNOWN","sponsor":"Guangzhou Psychiatric Hospital","startDate":"2012-01","conditions":"Schizophrenia","enrollment":170},{"nctId":"NCT01833897","phase":"PHASE4","title":"NMDA Antagonists in Bipolar Depression","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2013-03","conditions":"Bipolar Disorder","enrollment":8},{"nctId":"NCT00988728","phase":"PHASE2","title":"Efficacy & Safety of SCH 900435 in Schizophrenia (Study P06079)(WITHDRAWN)","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-02","conditions":"Schizophrenia","enrollment":""},{"nctId":"NCT00827918","phase":"PHASE2","title":"A Study to Test the Safety and Efficacy of MK-8998 in Acutely Psychotic Participants With Schizophrenia (MK-8998-004)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-03","conditions":"Schizophrenia","enrollment":216},{"nctId":"NCT00615433","phase":"PHASE3","title":"Lurasidone HCl A Phase 3 Study of Patients With Acute Schizophrenia","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2008-01","conditions":"Schizophrenia","enrollment":478},{"nctId":"NCT01234454","phase":"NA","title":"Atypical Antipsychotic Treatment Effect On Brain Function In Schizophrenia Measured By FMRI","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2002-01","conditions":"Schizophrenia","enrollment":34},{"nctId":"NCT00489593","phase":"PHASE1","title":"Olanzapine in Patients With Advanced Cancer and Weight Loss","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-10","conditions":"Advanced Cancer, Weight Loss","enrollment":57},{"nctId":"NCT01765829","phase":"PHASE3","title":"Clinical Trial to Evaluate the Efficacy of Treatment vs Discontinuation in a First Episode of Non-affective Psychosis","status":"UNKNOWN","sponsor":"Fundación Pública Andaluza Progreso y Salud","startDate":"2012-11","conditions":"Psychosis Nos/Other","enrollment":104},{"nctId":"NCT00183404","phase":"PHASE2, PHASE3","title":"Long-Term Olanzapine Treatment in Children With Autism","status":"COMPLETED","sponsor":"Drexel University","startDate":"2004-09","conditions":"Autism","enrollment":32},{"nctId":"NCT02040883","phase":"PHASE4","title":"Tandospirone Combined With Atypical Antipsychotic Drugs in Schizophrenia","status":"UNKNOWN","sponsor":"Qingyun Yin","startDate":"2014-02","conditions":"Schizophrenia","enrollment":100},{"nctId":"NCT00508157","phase":"PHASE4","title":"A Phase 4 Study to Assess the Effects of Aripiprazole Versus Other Atypical Antipsychotics in the Treatment of Schizophrenic Patients With Metabolic Syndrome","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2007-11","conditions":"Metabolic Syndrome, Schizophrenia","enrollment":125},{"nctId":"NCT00520923","phase":"PHASE2","title":"A Study for Patients With Schizophrenia","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2007-09","conditions":"Schizophrenia","enrollment":654},{"nctId":"NCT00528359","phase":"","title":"β-Cell Function in Schizophrenic Subjects on Atypical Antipsychotic drugS","status":"COMPLETED","sponsor":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","startDate":"2005-10","conditions":"Schizophrenia","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Phase 1: Olanzapine","genericName":"Phase 1: Olanzapine","companyName":"Shanghai Mental Health Center","companyId":"shanghai-mental-health-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Olanzapine is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain. Used for Schizophrenia, Bipolar I disorder (acute mania and maintenance treatment), Treatment-resistant depression (as adjunctive therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}